Pretargeting (imaging)

Edit links
From Wikipedia, the free encyclopedia
Schematic representation of a two-step pretargeting approach.

Pretargeting (imaging) is a tool for nuclear medicine and radiotherapy. Imaging studies require a high contrast of target to background. This can be provided by using a biomarker which has a high affinity and specificity for its target (e.g. an antibody).

History[edit]

The beginning of antibody imaging[edit]

Owing to their high affinity and specificity, antibodies have been considered as suitable vehicles for imaging and therapeutics, since the beginning of the 20th Century.[1][2][3]

The first radiolabelled antibodies were used in the early 1950s and got used for cancer therapy,[4][5] but it took roughly two more decades before it was demonstrated that they target human tumour associated antigens in cancer patients.[6] Due to the hybridoma technology in 1975, monoclonal (murine) antibodies could easily be produced in practical amounts,[7] consequently the number of studies increased drastically. However, these types of antibodies turned out to be quite troublesome, due to the triggering of the human anti-murine antibody response.[8] Consequently chimeric, humanised and human monoclonal antibodies have been created, produced and get used nowadays.[9]

Owing to the high molecular weight of antibodies and the Fc domain of the antibody,[10] a slow clearance from the blood and non-target tissue occurs, which results in low tumour-to-blood and tumour-to-muscle ratios.[11][12] Because of this, antibodies which are going to be used for imaging purposes need to be labelled with radionuclides that have a long half-life,[13] which increases the radiation dose to the patient. This consequently encouraged the development of lower molecular weight antibodies and resulted in the development of minibodies, diabodies, single chain variable fragments (scFv) and single domain fragments (Fv).[14]

Development of pretargeted imaging[edit]

To bypass the problem associated with the prolonged circulation time of radiolabelled antibodies, in the mid-1980s a strategy called pretargeted radioimmunotherapy was developed.[15][16] In short, this approach contained two important steps: 1. administration of a macromolecular targeting vector (usually antibody-based), and 2. a small radiolabelled molecule, which interacts with the targeting vector. Most importantly the small radiolabelled molecule gets injected after a predetermined lag period after which the macromolecule has had enough time to bind to its target and the residual unbound macromolecule to be cleared out of the system.[14] To ensure sufficient interaction between the two components, suitable modifications with complementary species are required (like bioorthogonal modifications).[17]

Pretargeting strategies can lead to an improved imaging contrast, as it combines the high target specificity and affinity of an antibody with the fast pharmacokinetic properties of a small molecule. The concept of pretargeting, although existing for several decades already, was limited to a few distinct classes. Developing chemical reactions that proceed quickly within living systems, without interacting with the large variety of existing functional groups, used to be an inherent difficulty. However, there have been several advancements in this area over the past few years.[14]

Conventional pretargeting systems[edit]

Bispecific antibodies and radiolabelled haptens[edit]

The beginning of the pretargeting concept was based on bispecific antibodies which were able to bind a specific target antigen and a radiolabelled hapten.[18][19][20][21][22][23] Possible was this approach because of the development of monoclonal Antibodies which could be connected to radiometal chelates.[15] Also connecting two haptens via a two amino acid linker resulted in an enhancement effect of the affinity, which improved the uptake and retention of the radiolabelled compound without affecting the rapid clearance.[24]

Limiting factor of this approach were the slow binding constant which was rarely higher than 10−10 M, amongst other reasons.[14]

Biotin-(strept)avidin[edit]

After the discovery of the fast interaction between Biotin and (Strept)Avidin, which show a high binding affinity, this approach has been used in many different ways (e.g. for protein purification purposes like the Step-tag).[25][26][27][28][29][30][31]

References[edit]

  1. ^ Wu, Anna M.; Olafsen, Tove (May 2008). "Antibodies for Molecular Imaging of Cancer". The Cancer Journal. 14 (3): 191–197. doi:10.1097/ppo.0b013e31817b07ae. ISSN 1528-9117. PMID 18536559. S2CID 36963226.
  2. ^ Knowles, Scott M.; Wu, Anna M. (2012-11-01). "Advances in Immuno–Positron Emission Tomography: Antibodies for Molecular Imaging in Oncology". Journal of Clinical Oncology. 30 (31): 3884–3892. doi:10.1200/JCO.2012.42.4887. ISSN 0732-183X. PMC 3478579. PMID 22987087.
  3. ^ Boerman, Otto C.; Oyen, Wim J. G. (2011-08-01). "Immuno-PET of Cancer: A Revival of Antibody Imaging". Journal of Nuclear Medicine. 52 (8): 1171–1172. doi:10.2967/jnumed.111.089771. ISSN 0161-5505. PMID 21764784. S2CID 22588904.
  4. ^ Pressman, David; Korngold, Leonhard (1953). "The in vivo localization of anti-Wagner-osteogenic-sarcoma antibodies". Cancer. 6 (3): 619–623. doi:10.1002/1097-0142(195305)6:3<619::aid-cncr2820060319>3.0.co;2-y. ISSN 1097-0142. PMID 13042784. S2CID 29001745.
  5. ^ Wisser, R.W (September 1956). "A Study of the Preparation, Localization, and Effects of Antitumor Antibodies Labeled with I131". Cancer Research. 16 (8): 761–773. PMID 13364902.
  6. ^ Goldenberg, David M.; DeLand, Frank; Kim, Euishin; Bennett, Sidney; Primus, F. James; van Nagell, John R.; Estes, Norman; DeSimone, Philip; Rayburn, Pam (1978-06-22). "Use of Radio-Labeled Antibodies to Carcinoembryonic Antigen for the Detection and Localization of Diverse Cancers by External Photoscanning". New England Journal of Medicine. 298 (25): 1384–1388. doi:10.1056/NEJM197806222982503. ISSN 0028-4793. PMID 349387.
  7. ^ Köhler, G.; Milstein, C. (August 1975). "Continuous cultures of fused cells secreting antibody of predefined specificity". Nature. 256 (5517): 495–497. Bibcode:1975Natur.256..495K. doi:10.1038/256495a0. ISSN 1476-4687. PMID 1172191. S2CID 4161444.
  8. ^ Tjandra, J. J.; Ramadi, L.; McKenzie, I. F. (December 1990). "Development of human anti-murine antibody (HAMA) response in patients". Immunology and Cell Biology. 68 ( Pt 6) (6): 367–376. doi:10.1038/icb.1990.50. ISSN 0818-9641. PMID 1711007. S2CID 9138513.
  9. ^ Chames, Patrick; Van Regenmortel, Marc; Weiss, Etienne; Baty, Daniel (May 2009). "Therapeutic antibodies: successes, limitations and hopes for the future". British Journal of Pharmacology. 157 (2): 220–233. doi:10.1111/j.1476-5381.2009.00190.x. ISSN 0007-1188. PMC 2697811. PMID 19459844.
  10. ^ Lee, Chang-Han; Kang, Tae Hyun; Godon, Ophélie; Watanabe, Makiko; Delidakis, George; Gillis, Caitlin M.; Sterlin, Delphine; Hardy, David; Cogné, Michel; Macdonald, Lynn E.; Murphy, Andrew J. (December 2019). "An engineered human Fc domain that behaves like a pH-toggle switch for ultra-long circulation persistence". Nature Communications. 10 (1): 5031. Bibcode:2019NatCo..10.5031L. doi:10.1038/s41467-019-13108-2. ISSN 2041-1723. PMC 6834678. PMID 31695028.
  11. ^ Rosebrough, S. F.; Grossman, Z. D.; McAfee, J. G.; Kudryk, B. J.; Subramanian, G.; Ritter-Hrncirik, C. A.; Witanowski, L. S.; Tillapaugh-Fay, G.; Urrutia, E.; Zapf-Longo, C. (July 1988). "Thrombus imaging with indium-111 and iodine-131-labeled fibrin-specific monoclonal antibody and its F(ab')2 and Fab fragments". Journal of Nuclear Medicine. 29 (7): 1212–1222. ISSN 0161-5505. PMID 3392581.
  12. ^ Murray, J. L.; Rosenblum, M. G.; Lamki, L.; Glenn, H. J.; Krizan, Z.; Hersh, E. M.; Plager, C. E.; Bartholomew, R. M.; Unger, M. W.; Carlo, D. J. (January 1987). "Clinical parameters related to optimal tumor localization of indium-111-labeled mouse antimelanoma monoclonal antibody ZME-018". Journal of Nuclear Medicine. 28 (1): 25–33. ISSN 0161-5505. PMID 3794809.
  13. ^ Deri, Melissa A.; Zeglis, Brian M.; Francesconi, Lynn C.; Lewis, Jason S. (January 2013). "PET Imaging with 89Zr: From Radiochemistry to the Clinic". Nuclear Medicine and Biology. 40 (1): 3–14. doi:10.1016/j.nucmedbio.2012.08.004. ISSN 0969-8051. PMC 3517725. PMID 22998840.
  14. ^ a b c d Knight, James C; Cornelissen, Bart (2014-03-20). "Bioorthogonal chemistry: implications for pretargeted nuclear (PET/SPECT) imaging and therapy". American Journal of Nuclear Medicine and Molecular Imaging. 4 (2): 96–113. ISSN 2160-8407. PMC 3992206. PMID 24753979.
  15. ^ a b Reardan, Dayton T.; Meares, Claude F.; Goodwin, David A.; McTigue, Maureen; David, Gary S.; Stone, Mary R.; Leung, Julia P.; Bartholomew, Richard M.; Frincke, James M. (July 1985). "Antibodies against metal chelates". Nature. 316 (6025): 265–268. Bibcode:1985Natur.316..265R. doi:10.1038/316265a0. ISSN 0028-0836. PMID 3927170. S2CID 4273142.
  16. ^ Goodwin, D. A.; Mears, C. F.; McTigue, M.; David, G. S. (August 1986). "Monoclonal antibody hapten radiopharmaceutical delivery". Nuclear Medicine Communications. 7 (8): 569–580. doi:10.1097/00006231-198608000-00002. ISSN 0143-3636. PMID 3095721. S2CID 31950034.
  17. ^ Goodwin, D. A.; Meares, C. F.; McCall, M. J.; McTigue, M.; Chaovapong, W. (February 1988). "Pre-targeted immunoscintigraphy of murine tumors with indium-111-labeled bifunctional haptens". Journal of Nuclear Medicine. 29 (2): 226–234. ISSN 0161-5505. PMID 3346734.
  18. ^ Sharkey, Robert M.; Rossi, Edmund A.; Chang, Chien-Hsing; Goldenberg, David M. (February 2010). "Improved Cancer Therapy and Molecular Imaging with Multivalent, Multispecific Antibodies". Cancer Biotherapy and Radiopharmaceuticals. 25 (1): 1–12. doi:10.1089/cbr.2009.0690. ISSN 1084-9785. PMC 2883519. PMID 20187791.
  19. ^ Goldenberg, D. M.; Rossi, E. A.; Sharkey, R. M.; McBride, W. J.; Chang, C.-H. (2007-12-12). "Multifunctional Antibodies by the Dock-and-Lock Method for Improved Cancer Imaging and Therapy by Pretargeting". Journal of Nuclear Medicine. 49 (1): 158–163. doi:10.2967/jnumed.107.046185. ISSN 0161-5505. PMID 18077530. S2CID 32847549.
  20. ^ Goldenberg, David M.; Chatal, Jean-Francois; Barbet, Jacques; Boerman, Otto; Sharkey, Robert M. (March 2007). "Cancer imaging and therapy with bispecific antibody pretargeting". Update on Cancer Therapeutics. 2 (1): 19–31. doi:10.1016/j.uct.2007.04.003. PMC 2034280. PMID 18311322.
  21. ^ Sharkey, Robert M.; Karacay, Habibe; Goldenberg, David M. (2010). "Improving the treatment of non-Hodgkin lymphoma with antibody-targeted radionuclides". Cancer. 116 (S4): 1134–1145. doi:10.1002/cncr.24802. ISSN 1097-0142. PMC 2820147. PMID 20127947.
  22. ^ Sharkey, Robert M.; Rossi, Edmund A.; McBride, William J.; Chang, Chien-Hsing; Goldenberg, David M. (May 2010). "Recombinant Bispecific Monoclonal Antibodies Prepared by the Dock-and-Lock Strategy for Pretargeted Radioimmunotherapy". Seminars in Nuclear Medicine. 40 (3): 190–203. doi:10.1053/j.semnuclmed.2009.12.002. PMC 2855818. PMID 20350628.
  23. ^ Goldenberg, David M.; Chang, Chien-Hsing; Rossi, Edmund A.; J, William; McBride, null; Sharkey, Robert M. (2012). "Pretargeted molecular imaging and radioimmunotherapy". Theranostics. 2 (5): 523–540. doi:10.7150/thno.3582. ISSN 1838-7640. PMC 3364558. PMID 22737190.
  24. ^ Le Doussal, J. M.; Martin, M.; Gautherot, E.; Delaage, M.; Barbet, J. (August 1989). "In vitro and in vivo targeting of radiolabeled monovalent and divalent haptens with dual specificity monoclonal antibody conjugates: enhanced divalent hapten affinity for cell-bound antibody conjugate". Journal of Nuclear Medicine. 30 (8): 1358–1366. ISSN 0161-5505. PMID 2787847.
  25. ^ Hnatowich, D. J.; Virzi, F.; Rusckowski, M. (August 1987). "Investigations of avidin and biotin for imaging applications". Journal of Nuclear Medicine. 28 (8): 1294–1302. ISSN 0161-5505. PMID 3612292.
  26. ^ Michael Green, N. (1990), "[5] Avidin and streptavidin", Avidin-Biotin Technology, Methods in Enzymology, vol. 184, Elsevier, pp. 51–67, doi:10.1016/0076-6879(90)84259-j, ISBN 978-0-12-182085-5, PMID 2388586, retrieved 2020-09-30
  27. ^ Boerman, Otto C.; van Schaijk, Frank G.; Oyen, Wim J. G.; Corstens, Frans H. M. (March 2003). "Pretargeted radioimmunotherapy of cancer: progress step by step". Journal of Nuclear Medicine. 44 (3): 400–411. ISSN 0161-5505. PMID 12621007.
  28. ^ Liu, Guozheng; Hnatowich, Donald J. (2008-11-19). "A Semiempirical Model of Tumor Pretargeting". Bioconjugate Chemistry. 19 (11): 2095–2104. doi:10.1021/bc8002748. ISSN 1043-1802. PMC 2645947. PMID 18839978.
  29. ^ Sharkey, Robert M.; Chang, Chien-Hsing; Rossi, Edmund A.; McBride, William J.; Goldenberg, David M. (June 2012). "Pretargeting: taking an alternate route for localizing radionuclides". Tumor Biology. 33 (3): 591–600. doi:10.1007/s13277-012-0367-6. ISSN 1010-4283. PMID 22396041. S2CID 16162151.
  30. ^ Sharkey, Robert M.; Goldenberg, David M. (2006-01-01). "Advances in Radioimmunotherapy in the Age of Molecular Engineering and Pretargeting". Cancer Investigation. 24 (1): 82–97. doi:10.1080/07357900500449553. ISSN 0735-7907. PMID 16466997. S2CID 38314674.
  31. ^ Goldenberg, David M.; Sharkey, Robert M.; Paganelli, Giovanni; Barbet, Jacques; Chatal, Jean-François (2006-02-10). "Antibody Pretargeting Advances Cancer Radioimmunodetection and Radioimmunotherapy". Journal of Clinical Oncology. 24 (5): 823–834. doi:10.1200/jco.2005.03.8471. ISSN 0732-183X. PMID 16380412.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Pretargeting_(imaging)&oldid=1172460236"